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We have previously demonstrated that the Epstein–Barr virus immediate–early BZLF1 protein interacts with, and is inhibited by, the NF-
nB family member p65. However, the effects of BZLF1 on NF-nB activity have not been intensively studied. Here we show that BZLF1
inhibits p65-dependent gene expression. BZLF1 inhibited the ability of IL-1, as well as transfected p65, to activate the expression of two
different NF-nB-responsive genes, ICAM-1 and InB-a. BZLF1 also reduced the constitutive level of InB-a protein in HeLa and A549 cells,
and increased the amount of nuclear NF-nB to a similar extent as tumor necrosis factor-alpha (TNF-a) treatment. In spite of this BZLF1-
associated increase in the nuclear form of NF-nB, BZLF1 did not induce binding of NF-nB to NF-nB responsive promoters (as determined
by chromatin immunoprecipitation assay) in vivo, although TNF-a treatment induced NF-nB binding as expected. Overexpression of p65
dramatically inhibited the lytic replication cycle of EBV in 293-EBV cells, confirming that NF-nB also inhibits BZLF1 transcriptional
function. Our results are consistent with a model in which BZLF1 inhibits the transcriptional function of p65, resulting in decreased
transcription of InB-a, decreased expression of InB-a protein, and subsequent translocation of NF-nB to the nucleus. This nuclear
translocation of NF-nB may promote viral latency by negatively regulating BZLF1 transcriptional activity. In situations where p65 activity is
limiting in comparison to BZLF1, the ability of BZLF1 to inhibit p65 transcriptional function may protect the virus from the host immune
system during the lytic form of infection.
D 2004 Elsevier Inc. All rights reserved.
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Epstein–Barr virus (EBV) is a human g-herpesvirus that
persistently infects the majority of the world population.
Primary infection with EBV occurs in the oropharynx via
saliva exchange and may lead to the development of the
syndrome infectious mononucleosis (Kieff and Rickinson,
2001; Rickinson and Kieff, 2001). Additionally, EBV is
associated with an increasing number of human malignan-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: shann@med.unc.edu (S.C. Kenney).cies, of both lymphoid and epithelial origin, including
nasopharyngeal carcinoma, gastric carcinoma, Burkitt’s
lymphoma, post-transplant lymphoproliferative disease,
and Hodgkin’s lymphoma (Kieff and Rickinson, 2001;
Rickinson and Kieff, 2001).
EBV lytic infection is initiated by the expression of two
immediate–early (IE) genes, BZLF1 and BRLF1 (Cheval-
lier-Greco et al., 1986; Countryman and Miller, 1985;
Hardwick et al., 1992; Ragoczy et al., 1998; Rooney et al.,
1989; Takada et al., 1986; Urier et al., 1989; Zalani et al.,
1996). The BZLF1 gene product (BZLF1, Zta, ZEBRA,
EB1) is a member of the basic leucine zipper (b-zip) family
of DNA binding proteins that binds to AP-1-like sites,
termed Z response elements (ZREs), present in EBV IE and
early gene promoters (Chang et al., 1990; Farrell et al.,04) 219–232
T.E. Morrison, S.C. Kenney / Virology 328 (2004) 219–2322201989; Flemington and Speck, 1990; Flemington et al., 1992;
Lieberman et al., 1989). BZLF1 functions as a transcrip-
tional transactivator and, along with the other EBV IE gene
BRLF1, induces the lytic cascade of viral gene expression
(Feederle et al., 2000).
The NF-nB family of transcription factors are critical for
inducible expression of a wide variety of genes involved in
immunity and inflammation (Baldwin, 2001; Ghosh et al.,
1998). In unstimulated cells, the majority of NF-nB resides
in the cytoplasm in association with the InB family of
inhibitory molecules, which mask the nuclear localization
signals of NF-nB (Ghosh and Karin, 2002). The most
abundant form of NF-nB in most cells is a heterodimer of
p65/RelA and p50. NF-nB signaling is activated by a
variety of stimuli including cytokines and growth factors
that activate the InB kinase complex (IKK). Once activated,
IKK phosphorylates InB family members at conserved
serine residues (DiDonato et al., 1997; Mercurio et al.,
1997; Woronicz et al., 1997; Zandi et al., 1997). This
phosphorylation results in ubiquitin-mediated degradation
of InBs by the proteasome (Karin and Ben-Neriah, 2000).
Degradation of InB releases NF-nB to translocate to the
nucleus where it binds kB enhancer elements and modulates
gene expression. NF-nB also strongly activates the InB-a
promoter, allowing InB-a to be regenerated in cells and thus
terminate the NF-nB signaling cascade (Arenzana-Seisde-
dos et al., 1995; Brown et al., 1993; Chiao et al., 1994; Sun
et al., 1993).
Activation of NF-nB is a feature of many viral infections
(Mogensen and Paludan, 2001). NF-nB activation during
viral infection is believed to be a protective response of the
host to the viral pathogen. Therefore, many viruses have
evolved distinct strategies to control the activity of NF-nB
to evade the immune response (Hiscott et al., 2001; Santoro
et al., 2003). Additionally, viruses may modulate the NF-nB
pathway to enhance viral replication or prevent virus-
induced apoptosis (Hiscott et al., 2001; Santoro et al., 2003).
BZLF1 and p65 have been previously shown to directly
interact, and co-expression of p65 inhibited BZLF1 trans-
activation of several EBV lytic gene promoters (Gutsch et
al., 1994). However, the effects of BZLF1 on NF-nB
activity have not been extensively studied. Two studies
suggested that BZLF1 expression in B cells and T cell lines
decreased transcription of NF-nB reporter genes (Dreyfus et
al., 1999; Keating et al., 2002). In contrast, another study
reported that a DNA binding-defective BZLF1 activated the
expression of an NF-nB-responsive reporter construct
(Flemington et al., 1994). Thus, the effect of BZLF1 on
NF-nB transcriptional function remains unclear, particularly
in regard to its effect in the context of the intact cellular
genome.
Here, we show that BZLF1 inhibits p65-dependent gene
expression induced by either the IL-1 cytokine or trans-
fected p65 in the context of the cellular genome. BZLF1
decreases constitutive transcription of the p65-responsive
InB-a gene in HeLa and A549 cells, resulting in decreasedInB-a protein expression. Consistent with its ability to
inhibit InB-a expression, BZLF1 expression also induces
nuclear translocation of NF-nB, similar to the effect of TNF-
a treatment. In contrast to the effect of TNF-a, however,
chromatin immunoprecipitation assays demonstrated that
the nuclear NF-nB induced by BZLF1 did not bind to the
InB-a or ICAM-1 promoters in vivo. Overexpression of p65
inhibited the lytic replication cycle of EBV in 293-EBV
cells, confirming previous studies suggesting that NF-nB
inhibits BZLF1 transcriptional function. Our results are
consistent with a model in which BZLF1 inhibits p65-
mediated transcription, which results in decreased InB-a
expression and consequently increases NF-nB translocation
to the nucleus. The ability of BZLF1 to indirectly promote
nuclear translocation of NF-nB through its effects on InB-a
may promote viral latency by negatively regulating BZLF1
transcriptional activity. In contrast, in situations where p65
activity is limiting in comparison to BZLF1, the ability of
BZLF1 to inhibit p65 transcriptional function may protect
the virus from the host immune system during the lytic form
of infection.Results
BZLF1 inhibits p65-induced gene expression
The BZLF1 gene product has been previously shown to
interact with, and be inhibited by, the NF-nB family member
p65 (Gutsch et al., 1994). However, the effects of BZLF1 on
NF-nB activity have not been thoroughly investigated,
particularly in regard to the ability of p65 to activate genes
in the context of the cellular genome. To determine if
BZLF1 modulates p65-mediated gene expression, HeLa
cells were transfected with a FLAG-tagged p65 expression
vector (FLAG-p65) together with a control plasmid or a
plasmid expressing BZLF1. The ability of transfected p65 to
induce expression of two different NF-nB responsive genes
(ICAM-1 and InB-a) in the context of the cellular genome
was evaluated by immunoblot analysis. As expected,
transfection of HeLa cells with FLAG-p65 induced
ICAM-1 expression (Fig. 1A) as well as expression of
InB-a (Fig. 1A). However, co-transfection of BZLF1 with
FLAG-p65 greatly inhibited p65-induced ICAM-1 expres-
sion, as well as p65-induced InB-a expression (Fig. 1A). In
contrast to the effects observed in the intact cellular genome,
BZLF1 actually enhanced the ability of transfected p65 to
active NF-nB reporter constructs that contained the con-
sensus NF-nB binding motif, or the InB-a promoter, linked
to the secretory alkaline phosphatase gene (Figs. 1B, C).
Similar results were obtained using luciferase-based NF-nB
reporter constructs, indicating that these effects were not
reporter gene specific (data not shown). Immunoblot
analysis confirmed that the level of transfected p65 was
similar or actually greater in the presence of co-transfected
BZLF1 (Fig. 1B). These results suggest that in the context
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of at least a subset of NF-nB responsive genes, and that this
effect cannot be adequately modeled using reporter gene
constructs.
Previous studies have demonstrated that CBP function-
ally interacts with p65 and enhances p65-mediated trans-
activation (Gerritsen et al., 1997). Similarly, BZLF1 also
directly interacts with CBP (Adamson and Kenney, 1999;
Chen et al., 2001; Deng et al., 2003; Zerby et al., 1999).Fig. 2. BZLF1 inhibition of p65 function is not reversed by CBP. HeLa cells
were transfected with 500 ng of a HA-tagged CBP expression plasmid
along with 500 ng of vector, FLAG-tagged p65, or BZLF1 expression
plasmids. Immunoblot analyses were performed with anti-CBP, anti-ICAM-
1, anti-BZLF1, anti-FLAG antibodies, and anti-h-actin antibodies.Thus, BZLF1 may inhibit p65-mediated gene expression
by competing for limiting amounts of cellular CBP. To test
this hypothesis, HeLa cells were transfected with FLAG-
p65, HA-CBP, and BZLF1 expression plasmids and
immunoblot analysis was performed for ICAM-1 expres-
sion. Although co-transfection of HA-CBP enhanced p65-
induced ICAM-1 expression, the ability of BZLF1 to
inhibit p65 induction of ICAM-1 was not affected by
overexpression of CBP (Fig. 2). Thus, competition for
limiting amounts of CBP in the cell cannot completely
explain the BZLF1-mediated inhibition of p65-dependent
transcription in the context of the intact cellular genome.
To determine which domains of the BZLF1 protein are
required for inhibition of p65 function, HeLa cells were
transfected with FLAG-p65 together with plasmids encod-
ing wild-type BZLF1, BZLF1 carrying a point mutation
that abrogates the ability of BZLF1 to bind DNA
(ZA185K), and BZLF1 deleted for amino acids 24–86,
which removes the BZLF1 transactivation domain (ZDTA).
As shown in Fig. 3A, wild-type BZLF1, ZA185K, andFig. 1. BZLF1 inhibits p65-induced ICAM-1 and InB-a expression. (A)
HeLa cells were transfected with 500 ng each of vector, BZLF1, or FLAG-
tagged p65 expression plasmids. At 48 h post-transfection, immunoblot
analyses were performed with anti-InBa, anti-ICAM-1, anti-BZLF1, anti-
p65, and anti-h-actin antibodies. (B) HeLa cells were transfected with 500
ng each of vector, BZLF1, or FLAG-tagged p65 expression plasmids
together with 500 ng of pSEAP-NFnB reporter plasmid. At 48 h post-
transfection, SEAP activity was assayed in tissue culture supernatants.
Immunoblot analyses were performed with anti-FLAG, anti-BZLF1, and
anti-h-actin antibodies. (C) HeLa cells were transfected with 500 ng each of
vector, BZLF1, or FLAG-tagged p65 expression plasmids together with
500 ng of pSEAP-InB-a reporter plasmids. At 48 h post-transfection, SEAP
activity was assayed in tissue culture supernatants.
Fig. 4. BZLF1 inhibits IL-1 induced ICAM-1 expression. (A) HeLa cells
were mock-infected or infected with adenovirus expressing LacZ (AdlacZ)
or BZLF1 (AdZ) (moi of 30). At 30 h post-infection, cells were
unstimulated or stimulated with 10 ng/ml TNF-a, 10 ng/ml LT-a, or 10
ng/ml IL-1 for 12 h. Immunoblot analysis was performed with anti-ICAM-1
and anti-h-actin antibodies. (B) HeLa cells were infected with AdlacZ or
AdZ (moi 30). At 48 h post-infection, cells were unstimulated or stimulated
with 10 ng/ml TNF-a or 10 ng/ml IL-1 for 10 min. Immunoblot analysis
was performed with anti-phospho-p65 (serine 536) and anti-p65 antibodies.
Fig. 3. BZLF1 inhibition of p65-mediated gene expression does not require
the BZLF1 transactivation domain or BZLF1 DNA binding. (A) HeLa cells
were transfected with 500 ng each of FLAG-tagged p65 expression plasmid
and various wild-type and mutant BZLF1 expression plasmids. Immunoblot
analyses were performed with anti-ICAM-1, anti-BZLF1, and anti-FLAG
antibodies. (B) ICAM-1 immunoblots from two independent experiments
were quantitated using the ImageJ v1.32 program (NIH) and graphed with
p65-induced ICAM-1 expression set at 100%.
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fection of FLAG-p65. Quantitation of immunoblots from
two independent experiments by ImageJ (NIH) analysis
confirmed that BZLF1, ZA185K, and ZDTA significantly
inhibited p65-induced ICAM-1 expression (Fig. 3B). A
mutant form of BZLF1 with a deletion of the entire
dimerization domain (ZDDIM), which is required for the
direct interaction between BZLF1 and p65 (Gutsch et al.,
1994), as well as BZLF1 homodimerization, was also
tested for its ability to inhibit p65-mediated gene induc-
tion. Co-transfection of ZDDIM did not inhibit p65-
induced gene expression (data not shown); however, we
found that this particular mutant is consistently expressed
at lower levels than wild-type and other mutant forms of
BZLF1 making the results difficult to interpret. These
findings suggest that the ability of BZLF1 to inhibit p65-
induced gene expression does not require the BZLF1
transactivation domain or BZLF1 DNA binding, making it
unlikely that BZLF1 indirectly inhibits p65 function by
inducing expression of a cellular gene product that inhibits
p65 transactivation.BZLF1 inhibits IL-1 induced ICAM-1 expression
The ability of BZLF1 to inhibit gene expression induced
by direct p65 transfection prompted us to test whether
BZLF1 also inhibits gene expression induced by cytokines
that signal via NF-nB activation. To test this hypothesis,
HeLa cells were mock-infected or infected with adenovirus
vectors expressing either the LacZ gene (AdlacZ) or the
BZLF1 gene (AdZ), and at 30 h post-infection cells were
unstimulated or stimulated with TNF-a, LT-a, or IL-1. In
mock-infected or AdlacZ-infected HeLa cells, stimulation
with TNF-a, LT-a, or IL-1 induced expression of ICAM-1
(Fig. 4A). As we have previously shown, BZLF1 inhibits
multiple cellular responses to TNF-a, a major inducer of
NF-nB, by down-regulation of the cellular receptor for
TNF-a, TNF-R1 (Morrison et al., 2004). Consistent with
these previous findings, expression of BZLF1 inhibited
ICAM-1 expression induced by TNF-a and LT-a, cytokines
that utilize TNF-R1. However, BZLF1 also inhibited
ICAM-1 expression induced by IL-1 stimulation, which
does not depend upon the presence of TNF-R1. To
determine whether the upstream components of the IL-1
signaling pathway are functional in AdZ-infected cells, the
ability of IL-1 to induce p65 phosphorylation on serine 536
(which occurs upstream of p65 translocation) (Sizemore et
al., 1999, 2002; Yang et al., 2003) was examined using a
phospho-specific p65 (serine 536) antibody (Fig. 4B). As
expected, treatment with either TNF-a or IL-1 stimulated
Fig. 6. InB-a is decreased in cells expressing BZLF1. HeLa cells were
mock-infected or infected with AdlacZ or AdZ (moi 30). At 48 h post-
infection, cells were treated with 10 ng/ml TNF-a for 30 min and extracts
were analyzed by immunoblot analysis for p65 (upper panel), InB-a
(middle panel), and h-actin (lower panel).
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but TNF-a did not stimulate p65 phosphorylation in AdZ-
infected cells because these cells do not express TNF-R1. In
contrast to the effect of TNF-a, treatment of AdZ-infected
cells with IL-1 resulted in phosphorylation of p65. Taken
together, these results suggest that upstream components of
the IL-1 signaling pathway are intact in AdZ-infected cells,
and that BZLF1 inhibits IL-1 induced ICAM-1 expression
downstream of NF-nB activation.
BZLF1 decreases IjB-a RNA expression
To determine if the ability of BZLF1 to prevent p65-
mediated induction of InB-a (Fig. 1A) is due to a decrease
in InB-a message, we examined the effect of AdZ on InB-a
RNA expression. Northern blot analysis on total RNA
demonstrated decreased expression of InB-a RNA in AdZ-
infected HeLa cells compared to cells infected with a control
adenovirus and mock-infected cells in the presence or
absence of TNF-a (Fig. 5). In contrast, the level of GAPDH
RNAwas unaffected. Similar results were obtained in A549
cells (data not shown). These results suggest that BZLF1
dramatically decreases the level of InB-a message in
epithelial cells.
BZLF1 decreases IjB-a protein expression
To further investigate the effect of BZLF1 expression on
InB-a, HeLa cells were mock-infected or infected with
AdlacZ or AdZ, and immunoblot analysis was performed to
examine expression of p65 and its endogenous inhibitor
InB-a in the presence or absence of TNF-a. Infection of
HeLa cells with AdZ did not affect the total level of p65
expression (Fig. 6). As predicted by the Northern blot
analysis in Fig. 5, InB-a protein expression was greatly
decreased in AdZ-infected cells. The AdZ-mediated
decrease in InB-a protein was as great or greater than that
induced by 30 min of TNF-a stimulation (Fig. 6), which is
known to induce InB-a degradation.Fig. 5. BZLF1 decreases InB-a RNA level. HeLa cells were mock-infected
or infected with AdlacZ or AdZ (moi 30). Total RNAwas harvested at 48 h
post-infection and analyzed by Northern blot analysis using radiolabeled
probes for InB-a (upper panel) or GAPDH (lower panel).InB-a protein is commonly regulated by phosphoryla-
tion-dependent ubiquitin-mediated degradation by the
proteasome (Karin and Ben-Neriah, 2000). To test
whether AdZ enhanced proteasomal-mediated degradation
of InB-a, HeLa cells were infected with AdlacZ or AdZ,
treated with DMSO or 50 AM MG-132 for 4, 6, and 10 h,
and extracts analyzed by immunoblot analysis for InB-a.
InB-a expression remained decreased in AdZ-infected
cells treated with the proteasome inhibitor (Fig. 7).
Immunoblot analysis for p53 demonstrated accumulation
of this protein in groups treated with MG-132, confirming
that the proteasome inhibitor was functional. These results
indicate that AdZ decreased InB-a expression occurs
mainly (if not entirely) through a decrease in InB-a
message.
BZLF1 induces accumulation of nuclear NF-jB
NF-nB is retained in the cytoplasm by its direct
interaction with InB-a. Thus, the finding that BZLF1
expression rather dramatically reduces InB-a expression
in HeLa cells suggested that BZLF1 may also induceFig. 7. BZLF1-mediated InB-a decrease is not reversed by proteasome
inhibition. HeLa cells were infected with AdlacZ or AdZ (moi 30). At 40 h
post-infection, cells were treated with DMSO or 50 AM MG-132 for the
times indicated, and extracts were analyzed by immunoblot analysis for
InB-a, p53, and h-actin.
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location of NF-nB in the presence of BZLF1, HeLa cells
were either mock-infected, infected with AdlacZ, or
infected with AdZ, and at 24 and 36 h post-infection,
cells were harvested and fractionated into their cytoplas-
mic and nuclear compartments. As shown in Fig. 8, AdZ
induced nuclear accumulation of p65 at both 24 and 36 h
post-infection. Significantly, the AdZ-induced nuclear
accumulation of p65 at 36 h post-infection was similar
to the level of p65 nuclear accumulation following 30
min of TNF-a stimulation. Immunoblot analysis con-
firmed that InB-a expression was decreased in the
cytoplasm of AdZ-infected cells at both 24 and 36 h
(data not shown).
Electrophoretic mobility shift assays (EMSA) were
performed to further confirm that BZLF1 induces nuclear
NF-nB in HeLa cells. Nuclear extracts were prepared from
HeLa cells infected with AdlacZ or with AdZ at 36 h post-
infection, or from AdlacZ-infected cells treated with TNF-
a for 30 min. As expected, nuclear extracts from TNF-a
treated (AdlacZ-infected) cells had greatly increased bind-
ing to a labeled probe containing the NF-nB binding site
from the MHC class I promoter (Fig. 9A), the InB-a
promoter (Fig. 9B), and the ICAM-1 promoter (Fig. 9B) in
comparison to the AdlacZ-infected cells not treated with
TNF-a. However, even in the absence of TNF-a treatment,
nuclear extracts prepared from the AdZ-infected cells had
significant binding to all three NF-nB-site containing
probes (Figs. 9A, B). Similar to the TNF-a-induced
binding complex, the AdZ-induced complex was super-
shifted with both anti-p65 and anti-p50 antibodies (Fig.
9A), confirming that the complex represents NF-nB.
EMSA analysis with a labeled probe containing the c/
EBP consensus site demonstrated similar binding of c/
EBP-h (Fig. 9C) (the major c/EBP isoform found in the
nucleus of HeLa cells), confirming that the increased
binding observed in nuclear extracts from AdZ-infected
cells was specific for NF-nB (Fig. 9C). The BZLF1 protein
also bound the c/EBP consensus site probe (Fig. 9C),Fig. 8. BZLF1 induces nuclear accumulation of p65. HeLa cells were
infected with AdlacZ or AdZ (moi 30), and nuclear and cytoplasmic extracts
were analyzed by immunoblot analysis for p65, BZLF1, and h-actin.confirming expression of BZLF1 in these extracts. These
results suggest that BZLF1 expression in HeLa cells results
in nuclear translocation of NF-nB, similar to that observed
following TNF-a treatment.
BZLF1 inhibits NF-jB binding to cellular promoters in the
context of the intact cellular genome
The previous results indicate that BZLF1 expression in
HeLa cells results in increased nuclear NF-nB binding
activity as measured by EMSA, yet paradoxically
decreases the ability of transfected p65, or IL-1 treatment,
to activate NF-nB-dependent transcription in the context of
the intact cellular genome. Therefore, we examined the
effect of BZLF1 on NF-nB DNA binding to NF-nB
responsive promoters in vivo using chromatin immunopre-
cipitation (ChIP) analysis. ChIP analysis detected recruit-
ment of p65 and p50 to the InB-a and ICAM-1 promoters
in AdlacZ-infected HeLa cells following TNF-a stimula-
tion, as expected (Fig. 10A). The HSP-70 control showed
that this TNF-a-dependent recruitment was specific to NF-
nB regulated promoters (Fig. 10A). In contrast, in AdZ-
infected HeLa cells, we were unable to detect p65 or p50
recruitment to either the InB-a or ICAM-1 promoters,
although the effect of BZLF1 on InB-a protein in this
experiment was at least as great as the TNF-a effect (Fig.
10B). PCR using serial dilutions of input DNA confirmed
an equal level of starting material in each experimental
condition (data not shown). These results suggest that
BZLF1 inhibits at least a subset of NF-nB-dependent gene
expression by reducing the ability of NF-nB to bind to NF-
nB responsive promoters in the context of the intact
cellular genome.
p65 overexpression inhibits BZLF1-mediated lytic cycle
induction in 293 cells
Although it has previously been demonstrated that p65
overexpression inhibits the ability of BZLF1 to trans-
activate reporter constructs containing the promoters of
the EBV early genes BHLF1 or BMRF1 (Gutsch et al.,
1994), the effect of p65 on BZLF1 function in the
context of the intact viral genome has not been well
studied. To determine if p65 expression inhibits the
ability of BZLF1 to induce the complete EBV lytic
replication cycle, 293 cells carrying the EBV genome
(Feederle et al., 2000) were transfected with an expres-
sion vector encoding BZLF1 in the presence or absence
of co-transfected p65. At 48 h post-transfection, cell
lysates were harvested and cell culture supernatants were
collected, centrifuged, and filtered. As shown by immu-
noblot analysis in Fig. 11A, transfected BZLF1 alone
induced expression of the other immediate–early gene
product, BRLF1, and the EBV early gene product,
BMRF1, in 293-EBV cells. The ability of BZLF1 to
induce expression of either BRLF1 or BMRF1 was
Fig. 9. BZLF1 induces nuclear NFnB DNA binding. HeLa cells were infected with AdlacZ or AdZ (moi 30). At 48 h post-infection, some groups were treated
with 10 ng/ml TNF-a for 30 min. Ten micrograms of nuclear extract were analyzed by electrophoretic mobility shift assay using radiolabeled probes containing
the NF-nB binding site from the major histocompatibility complex I promoter (A), the InB-a promoter (B), or the ICAM-1 promoter (B). Extracts were also
analyzed using a radiolabeled probe containing the c/EBP consensus site (C). Antibody supershifts were performed with anti-p65 and anti-p50 antibodies (A)
as well as anti-c/EBP-a and anti-c/EBP-h antibodies (C).
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with this, the infectious viral titer of the BZLF1-
transfected cell supernatants (determined by quantitating
the number of GFP-positive Raji B cells derived from
each supernatant) was also dramatically reduced by p65
overexpression (Fig. 11B). These results confirm that p65
inhibits BZLF1 transactivation function and further
demonstrate that p65 inhibits the complete EBV lytic
replication cycle.Discussion
NF-nB is a key mediator of the immune response and is
utilized by the host to initiate a rapid cellular response to a
wide range of stimuli. Target genes include cytokines,
chemokines, receptors required for immune recognition,
proteins involved in antigen presentation, and adhesion
receptors (Ghosh et al., 1998). Thus, it is an attractive target
to viral pathogens (Hiscott et al., 2001). In this report, we
Fig. 10. BZLF1 prevents NF-nB recruitment to the InB-a and ICAM-1
promoters in vivo. (A) HeLa cells were infected with AdlacZ or AdZ
(moi 30). Following stimulation of some groups with 10 ng/ml TNF-a for
30 min, chromatin immunoprecipitation using anti-p65, anti-p50, and
control rabbit IgG antibodies was performed to analyze the recruitment of
NF-nB to the InB-a, ICAM-1, and HSP-70 promoters. (B) Immunoblot
analysis of protein extracts from (A) for p65, InB-a, and h-actin.
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between BZLF1 and NF-nB. We present evidence that the
EBV immediate–early protein, BZLF1, inhibits gene
expression regulated by the NF-nB family member p65.
This ability of BZLF1 to inhibit NF-nB transcriptional
function may protect the lytic form of EBV infection from
the multiple immune-enhancing roles of NF-nB. Addition-
ally, we demonstrate that p65 overexpression inhibits the
complete EBV lytic replication cycle. Thus, cells that
express a high level of active NF-nB may more easily enter
the latent (versus lytic) form of EBV infection following
primary infection with this virus. Perhaps most surprisingly,
we find that BZLF1 expression results in efficient trans-
location of NF-nB to the nucleus, presumably due to
BZLF1-mediated inhibition of InB-a expression. Never-
theless, our evidence suggests that this nuclear NF-nB
cannot actually activate cellular genes in the presence of
BZLF1. Instead, NF-nB nuclear translocation may serve to
negatively autoregulate BZLF1 transcriptional activity and
thus promote viral latency. In addition, the ability of BZLF1
to enhance translocation of NF-nB to the nucleus mayenhance its direct association with p65, allowing it to inhibit
p65 transcriptional function.
The BZLF1-mediated induction of NF-nB translocation
to the nucleus is comparable to that which is found in the
nucleus of HeLa cells following stimulation with TNF-a.
Our data suggest that the nuclear translocation of NF-nB in
BZLF1-expressing cells, similar to the effect of TNF-a,
results from a dramatic decrease in the cellular level of InB-
a protein. In the absence of InB-a, NF-nB is not retained in
the cytoplasm and instead translocates to the nucleus.
However, both the mechanism by which BZLF1 induces a
decrease in InB-a expression, as well as the downstream
consequences of this effect, are very different from the
effects of TNF-a. Whereas TNF-a induces phosphorylation
and subsequent destabilization of the InB-a protein (Karin
and Ben-Neriah, 2000), BZLF1 does not appear to affect
InB-a protein stability but instead reduces InB-a tran-
scription. In addition, whereas the nuclear NF-nB induced
by TNF-a treatment results in increased transcription of NF-
nB responsive cellular genes, including the InB-a gene
(Ghosh et al., 1998), we found no evidence that the nuclear
NF-nB induced by BZLF1 activated either the ICAM-1 or
InB-a genes in the context of the cellular genome. We
conclude that the nuclear NF-nB induced by BZLF1
expression is unable to activate transcription of at least a
subset of NF-nB target genes in the context of the intact
cellular genome.
The exact mechanism by which BZLF1 prevents NF-
nB-dependent transcription of cellular genes is not totally
clear. Because BZLF1 and p65 physically associate
(Gutsch et al., 1994), one possibility is that the interaction
between BZLF1 and p65 inhibits p65 binding to DNA.
However, the EMSA experiments in Fig. 9 indicate that
nuclear NF-nB binding several probes is actually increased
by BZLF1 (due to translocation of NF-nB to the nucleus)
and thus do not support this hypothesis. It is possible that
the p65/BZLF1 complex cannot withstand the EMSA
conditions, thereby obscuring an effect of BZLF1 on NF-
nB binding. However, our finding that BZLF1 increases
the ability of transfected p65 to activate the InB-a
promoter linked to a reporter gene (Fig. 1B) suggests that
nuclear NF-nB binds to the InB-a promoter in the
presence of BZLF1 in at least some circumstances.
Nevertheless, the results of chromatin immunoprecipitation
analysis suggest that NF-nB cannot be efficiently recruited
to either the InB-a or ICAM-1 promoter in the context of
the intact cellular genome in BZLF1-expressing cells.
Thus, our data suggest that an epigenetic modification of
the InB-a promoter that occurs in the cellular genome,
such as histone deacetylation or methylation, but is not
adequately modeled using plasmid promoter constructs, is
required to observe BZLF1 reduction of NF-nB binding to
the InB-a promoter.
Interestingly, BZLF1 interacts directly with the histone
acetylase protein, CBP, and the interaction between CBP
and p65 also enhances p65 transcriptional function (Gerrit-
Fig. 11. p65 inhibits induction of the EBV lytic cycle by BZLF1. (A) 293-EBV cells were transfected with expression vectors encoding p65 and BZLF1 as
indicated. At 48 h post-transfection, cells were harvested and analyzed by immunoblot analysis for BZLF1 (upper panel), BRLF1 (middle panel), and BMRF1
(lower panel). (B) Raji cells were incubated with filtered cell supernatants from transfected 293-EBV cells (A). After 72 h of incubation, Raji cells were
analyzed for GFP expression using an inverted immunofluorescent microscope (lower panel), or the percentage of GFP-expressing cells was determined by
FACS analysis (upper panel).
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transcriptional function, at least partially, by competing for
limiting quantities of CBP in the host cell. Our finding that
CBP overexpression did not reverse the inhibitory effect of
BZLF1 on p65 argues against this mechanism, however. In
addition, mutational analysis showed that neither the BZLF1
transactivation domain (which is required for interaction
with CBP) (Adamson and Kenney, 1999; Zerby et al., 1999)
nor BZLF1 DNA binding are required for inhibition of p65-
mediated gene expression by BZLF1. These results suggest
that neither the direct interaction between BZLF1 and CBP,
nor the ability of BZLF1 to function as a transcription
factor, is required for inhibition of p65 function.
The ability of BZLF1 to inhibit NF-nB responsive gene
expression in the host cell may play an important role in
protecting the virus from the host immune response during
the lytic form of infection. Consistent with this, Keating andcolleagues recently reported that the cell surface expression
of three different NF-nB activated gene products, MHC
class I (Baldwin and Sharp, 1988; Israel et al., 1987), CD40
(Krzesz et al., 1999; Wagner et al., 2002), and ICAM-1
(Roebuck and Finnegan, 1999), is reduced on the surface of
BZLF1 (+) lymphoblastoid cells (Keating et al., 2002).
Thus, the level of BZLF1 expressed during infection of B
cells in the context of the intact virus appears to be sufficient
to inhibit expression of NF-nB-dependent gene products.
These results, together with this report, strongly support the
hypothesis that BZLF1 inhibits NF-nB-mediated gene
expression, which may be an important mechanism utilized
by the virus to evade host immune and inflammatory
responses.
In addition to the effects of BZLF1 on the NF-nB
pathway, the EBV latent membrane protein 1 (LMP1) is a
transmembrane protein that constitutively activates NF-nB
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Paine et al., 1995). Interestingly, LMP1 impairs induction
of the EBV lytic cycle (Adler et al., 2002; Prince et al.,
2003), and one mechanism of LMP1-mediated inhibition
of the lytic cycle is via NF-nB activation, as expression of
a dominant-negative InB-a abolished this activity (Prince
et al., 2003). Additionally, activated CD40, an inducer of
NF-nB activation, also inhibits induction of the EBV lytic
cycle (Adler et al., 2002). Taken together, these data
demonstrate that NF-nB is an important negative regulator
of the EBV lytic cycle.
It is well established that NF-nB induces several genes
with anti-apoptotic function (Ghosh et al., 1998). Thus, a
potential negative consequence for the virus in regard to
blocking NF-nB function would be the tendency to
promote apoptosis, which might decrease the efficiency
of viral replication. However, because EBV encodes
several different lytic gene products, including a bcl-2
homologue, that have anti-apoptotic function, these gene
products likely inhibit cellular apoptosis even in the
absence of functional NF-nB (Kieff and Rickinson,
2001). Additionally, our group has recently reported that
BZLF1 expression inhibits cellular responses to TNF-a,
including apoptosis, by down-regulating TNF-R1 expres-
sion (Morrison et al., 2004).
There is increasing evidence that NF-nB plays a
critical role in the regulation of gammaherpesviruses.
Our findings demonstrate that p65 inhibits lytic viral gene
expression and the production of new EBV virions when
co-transfected with a BZLF1 expression plasmid into
latently infected 293 cells. These results suggest that cells
that have a high level of active NF-nB at the time of
primary EBV infection may be more prone to entering the
latent form of infection than cells that have little or no
active NF-nB. Similar to results reported here, Brown et
al. (2003) found that overexpression of p65 inhibited lytic
viral gene expression and release of progeny virus in cells
infected with murine gammaherpesvirus-68 (MHV-68).
Additionally, treatment of at least one EBV-positive
Burkitt’s lymphoma line (P3J-HR1), and two different
KSHV-positive primary effusion lymphoma lines (BCBL1
and KS-1), with the NF-nB inhibitor Bay11-7082,
induced lytic viral gene expression, suggesting that
endogenous NF-nB actively suppresses the EBV and
KSHV lytic cycle (Brown et al., 2003). However, we
have not found that NF-nB inhibitors are sufficient to
induce lytic gene expression in EBV-transformed (lym-
phoblastoid) B-cell lines, indicating that additional factors
are also important for maintaining viral latency in these
cells (unpublished data).
Interestingly, herpes simplex virus-1 (HSV-1) infection
of C33 cells was also shown to result in decreased
expression of InBs and increased nuclear NF-nB (Patel et
al., 1998). HSV-1-induced NF-nB nuclear translocation was
shown to require expression of the HSV-1 IE proteins ICP4
and ICP27 (Patel et al., 1998). Similar to our findings, thenuclear NF-nB translocation resulting from HSV-1 infection
did not appear to result in an induction of NF-nB-dependent
gene expression (Patel et al., 1998). However, in contrast to
the evidence suggesting that NF-nB negatively regulates the
lytic replication cycle of gammaherpesviruses, increased
nuclear NF-nB enhanced HSV-1 replication (Patel et al.,
1998).
In summary, we have demonstrated that BZLF1 inhibits
gene expression induced by NF-nB; likewise, NF-nB
inhibits the EBV lytic replication cycle induced by BZLF1.
Somewhat surprisingly, we have demonstrated that BZLF1
translocates NF-nB to the nucleus, although the NF-nB in
the nucleus does not appear to be functional.Materials and methods
Cell lines
The HeLa line, a cervical carcinoma cell line, and A549
cells were maintained in Dulbecco’s modified Eagle’s
medium H supplemented with 10% fetal bovine serum
(FBS). 293-EBV cells (a gift from Henri–Jacques Dele-
cluse) were maintained in Dulbecco’s modified Eagle’s
medium H supplemented with 10% FBS. The Raji cell line,
a Burkitt’s lymphoma cell line, was maintained in RPMI
1640 medium supplemented with 10% FBS. All culture
media contained penicillin (100 U/ml) and streptomycin
(100 Ag/ml). All cell lines were cultured at 37 8C in a
humidified atmosphere containing 5% CO2.
Adenovirus construction and infection
The EBV IE gene BZLF1 and the control lacZ gene,
under control of the IE CMV promoter, were inserted via
cre-loxP-mediated recombination into an adenovirus type 5
derivative lacking the E1 and E3 genes to create adenovirus-
LacZ (AdlacZ) and adenovirus-BZLF1 (AdZ), as previously
described (Westphal et al., 1999). Recombinant virus stocks
were confirmed devoid of wild-type virus by plaque assay
and E1A Western blot. Cells were infected with no
adenovirus (mock infection), AdlacZ, or AdZ at the multi-
plicity of infection (moi) indicated.
Plasmid construction
Plasmids pSG5-Zwt and pSG5-ZA185K were con-
structed by subcloning wild-type BZLF1 cDNA or
A185K BZLF1 cDNA (containing a point mutation that
alters amino acid 185 from alanine to lysine) from the
pHD1013 vector into the EcoR1 site of pSG5 (Stratagene)
(Morrison et al., 2004). Plasmid pSG5-ZDTA was gen-
erated by HindIII cleavage of pSG5-Zwt followed by
religation, producing an in-frame deletion of amino acids
24–86 (Morrison et al., 2004). Plasmid pSG5-ZDDIM was
generated by subcloning BZLF1 cDNA containing a
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acid 196 to amino acid 228 (a gift from Alain Sergeant)
from the pKSV vector into the EcoR1 site of pSG5
(Stratagene). The FLAG-tagged p65 expression vector (a
gift from Albert Baldwin) encodes p65 cDNA under
control of the CMV promoter (Stein et al., 1993). The
HA-CBP expression vector contains the CBP cDNA
downstream of the CMV immediate–early promoter (a gift
from Jenny P.-Y. Ting). The pSEAP-NFnB reporter vector
contains four copies of the NFnB consensus sequence and
was obtained from Clontech. The reporter plasmid pSEAP-
InB-a was constructed by PCR amplification of a DNA
fragment corresponding to the 357/+ 68 region of the
InB-a promoter (relative to the transcription start site)
(Algarte et al., 1999; Ito et al., 1994; Le Bail et al., 1993)
using oligonucleotide primers to allow for addition of a 5V
NheI restriction site and a 3V BglII restriction site. The
PCR product was cloned upstream of the gene encoding
secreted alkaline phosphatase (SEAP) by cleavage with
NheI and BglII and ligation into NheI/BglII-digested
pSEAP2-Basic (Clontech), which lacks eukaryotic pro-
moter and enhancer sequences.
DNA transfection
Cell lines were transfected using FuGENE 6 trans-
fection reagent (Roche) according to the manufacturer’s
instructions. Briefly, cells were seeded into six-well plates
1 day before transfection. One microgram of plasmid
DNA was combined with 3 Al FuGENE 6 transfection
reagent in OptiMEM (Invitrogen) and added directly to
cell cultures. For reporter assays, 500 ng of each construct
was transfected. Transfection of pSEAP2-Basic with
effector plasmids was included as a control in each
experiment. Cells were incubated with transfection com-
plexes for 5 h.
Reporter assays
Secreted alkaline phosphatase (SEAP) activity was
measured in the supernatant of transfected cell cultures at
48 h post-transfection using a GreatEscAPeTM SEAP
chemiluminescent detection kit (CLONTECH) according
to the manufacturer’s protocol.
Immunoblotting
Cells were lysed in RIPA lysis buffer (50 mM Tris, pH
8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate,
0.1% sodium dodecyl sulfate [SDS] supplemented with
complete protease inhibitor cocktail [Roche]). Protein (30–
50 Ag) was diluted in an equal volume of 2 SDS sample
buffer, and SDS-polyacrylamide gel electrophoresis was
performed. Proteins were transferred overnight onto nitro-
cellulose membranes (Osmonics). Membranes were
blocked in 1 phosphate-buffered saline (PBS)/5% milk/0.1% Tween 20 and incubated in primary antibody for 1–2 h
at room temperature (ICAM-1 [1:500], p65 [1:200], InB-
a[1:1000], CBP [1:200] and p53 [1:200] from Santa
Cruz Biotechnology; h-actin [1:5000] and anti-FLAG
[1:1000] from Sigma; phospho-serine 536 of p65
[1:1000] from Cell Signaling Technology; BMRF1
[1:100] from Capricorn, BZLF1 [1:75] from Dako and
BZLF1 [1:500] from Argene). Membranes were washed
in PBS–0.1% Tween 20 and incubated with secondary
antibody for 1 h at room temperature (goat anti-rabbit–
horseradish peroxidase [HRP] or goat anti-mouse–HRP
[both 1:10,000] from Promega). Following washing,
proteins were visualized by enhanced chemiluminescence
(Amersham) according to the manufacturer’s instructions.
Immunoblots were quantitated using ImageJ v1.32
software (NIH).
Chromatin immunoprecipitation assays
HeLa cells (with or without TNF-a stimulation) were
cross-linked for 10 min at room temperature by adding
formaldehyde (37% from Sigma) directly to the culture
medium to a final concentration of 1%. Cross-linking was
stopped by the addition of glycine to a final concentration
of 125 mM for 5 min. Cells were washed 2 with ice-cold
1 PBS, scraped into 15-ml conical tubes, and centrifuged
for 10 min at 4 8C. Chromatin immunoprecipitations were
performed following a modification of the Chromatin
Immunoprecipitation Assay Kit protocol (Upstate). Briefly,
cells were lysed in 100 Al ChIP lysis buffer (50 mM Tris,
at pH 8.1, 10 mM EDTA, 1% SDS) supplemented with
complete protease inhibitors (Roche). Following dilution in
500 Al ChIP dilution buffer (16.7 mM Tris, pH 8.1, 150
mM NaCl, 1.2 mM EDTA, 1.1% Triton X-100, 0.01%
SDS), chromatin was sheared by sonication (power setting
3) with a Misonix XL-2020 sonicator (1 10-s burst, 2
35-s pulse [1.0 s ON, 0.8 s off], 1 10-s burst). Samples
were centrifuged to pellet debris and diluted 10 in ChIP
dilution buffer. Samples were precleared with 60 Al of a
50% slurry of salmon sperm/protein A agarose beads for
1 h at 4 8C and immunoprecipitations were carried out
overnight at 4 8C with 2 Ag each of anti-p65 (Santa Cruz),
anti-p50 (Santa Cruz), and purified rabbit IgG from normal
serum (Sigma). Immune complexes were collected with 60
Al of salmon sperm/protein A agarose beads for 2 h and
washed 1 for 15 min in low salt buffer, high salt buffer,
LiCl buffer, and 2 for 5 min in TE. Immune complexes
were eluted in 1% SDS/0.1 M Na HCO3 and cross-links
were reversed by heating at 65 8C for 5–6 h. Following
proteinase K digestion (45 8C for 1 h), DNA was phenol–
chloroform extracted once, chloroform extracted once, and
ethanol precipitated. Pellets were resuspended in 30 Al TE
and one-tenth of the immunoprecipitated DNA was used in
each PCR. The human HSP70 promoter was amplified
with the PCR primer pairs 5V-GGATCCAGTGTTCCGTT
TCC-3V and 5V-GTCAAACACGGTGTTCTGCG-3V (Nis-
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was amplified with the PCR primer pairs 5V-GAC-
GACCCCAATTCAAATCG-3V and 5V-TCAGGCTCGGG-
GAATTTCC-3V (Saccani et al., 2002). The human ICAM-1
promoter was amplified with the PCR primer pairs 5V-
ACCTTAGCGCGGTGTAGACC-3V and 5V-CTCCGGAA-
CAAATGCTGC-3V(Nissen and Yamamoto, 2000).
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared using a modification of
the Dignam method (Dignam et al., 1983). Briefly, cells
were resuspended in buffer A (20 mM HEPES, 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, and
complete protease inhibitor) with 1% NP-40. Crude nuclei
were pelleted at low speed, and the cytosolic fractions were
extracted. Nuclei were purified over an OptiPrep gradient
with 25%, 30%, and 35% layers and then lysed with NE
buffer (20 mM Tris–HCl, 400 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 25% glycerol, and complete protease
inhibitors). Oligonucleotides containing the NF-nB binding
site from the human MHC class I promoter (CAGG-
GCTGGGGATTCCCCATCTCCACAGTTTCACTTC) (a
gift from Albert Baldwin), the InB-a promoter (GCTT-
GGAAATTCCCCGAGCCT), and the ICAM-1 promoter
(TTAGCTTGGAAATTCCGGAGCTG), as well as oligonu-
cleotides containing the C/EBP consensus site (CTAGCTG-
CAGATTGCGCAATCTGCAG), were labeled with [a-32P]
dCTP using the Klenow fragment of DNA polymerase I
(Roche). Binding reactions contained 5–10 Ag nuclear
extract and 20,000 cpm radiolabeled oligonucleotide in
10 mM Tris, pH 7.6, 10% glycerol, 1 mM DTT, 0.5 mM
EDTA, and 2 Ag dIdC. For antibody supershift experi-
ments, 1 Al of antibody was incubated with nuclear extract
for 30 min before addition of radiolabeled probe. Binding
reactions were electrophoresed in 5% nondenaturing poly-
acrylamide gels in 1 Tris–Glycine–EDTA buffer. Gels
were dried and protein–DNA complexes were visualized by
autoradiography.
Northern blot analysis
Twenty micrograms of total RNA, purified using the
Qiagen RNeasy Mini Kit as specified by the manufacturer,
was separated on a 1% agarose/formaldehyde gel and
transferred to nylon membranes (Schleicher and Schuell).
Membranes were incubated for 25 min at 68 8C in QuikHyb
hybridization solution (Stratagene), and radiolabeled probes
were melted, mixed with 100 Al of 10 mg/ml calf thymus
DNA, and hybridized to membranes overnight at 68 8C.
After hybridization, membranes were washed twice in 2
SSC/0.1% SDS at room temperature and once in 0.2 SSC/
0.1% SDS for 30 min at 60 8C. The InB-a (a gift from
Albert Baldwin) and GAPDH (Ambion) DNA probes were
radiolabeled with 32P by random priming using an
oligolabeling kit (Amersham).Acknowledgments
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